Ernexa Therapeutics (ERNA) Institutional Ownership $1.88 -0.22 (-10.24%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Ernexa Therapeutics (NASDAQ:ERNA)CurrentInstitutional OwnershipPercentage70.55%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$1.04MNumber ofInstitutional Sellers(last 12 months)0 Get ERNA Insider Trade Alerts Want to know when executives and insiders are buying or selling Ernexa Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ERNA Institutional Buying and Selling by Quarter Ernexa Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/2025Geode Capital Management LLC257,310$76K0.0%+1,159.2%4.756% 5/3/2024Avidian Wealth Solutions LLC14,798$36K0.0%N/A0.274% 5/2/2024Sippican Capital Advisors72,800$175K0.1%+34.7%1.346% 2/13/2024Lake Street Advisors Group LLC520,996$933K0.1%N/A9.630% 1/30/2024Sippican Capital Advisors54,050$97K0.1%+92.3%0.999% 1/1/2024Vanguard Group Inc.24,898$54K0.0%+30.6%0.460% 10/24/2023Sippican Capital Advisors28,100$61K0.1%+30.1%0.519% 2/1/2023 Cypress Point Wealth Management LLC94,375$304K0.5%N/A3.210% 1/31/2023Naviter Wealth LLC79,621$387K0.1%N/A2.708% (Data available from 1/1/2016 forward) ERNA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ERNA shares? During the previous two years, the following institutional investors and hedge funds held shares of Ernexa Therapeutics shares: Lake Street Advisors Group LLC ($933K), Sippican Capital Advisors ($175K), Geode Capital Management LLC ($76K), and Vanguard Group Inc. ($54K), Avidian Wealth Solutions LLC ($36K).Learn more on Ernexa Therapeutics' institutional investors. What percentage of Ernexa Therapeutics' stock is owned by institutional investors? 70.55% of Ernexa Therapeutics' stock is owned by institutional investors. Learn more on ERNA's institutional investor holdings. Which institutional investors have been buying Ernexa Therapeutics' stock? The following institutional investors have purchased Ernexa Therapeutics' stock in the last 24 months: Lake Street Advisors Group LLC ($521.00K), Geode Capital Management LLC ($236.88K), Sippican Capital Advisors ($51.20K), Avidian Wealth Solutions LLC ($14.80K), and Vanguard Group Inc. ($5.83K). How much institutional buying is happening at Ernexa Therapeutics? Institutional investors have bought a total of 236,875 shares in the last 24 months. This purchase volume represents approximately $1.04M in transactions. Related Companies CUE Major Shareholders ATRA Major Shareholders ARTV Major Shareholders ADVM Major Shareholders VTVT Major Shareholders NRXP Major Shareholders KRON Major Shareholders PDSB Major Shareholders ANVS Major Shareholders AVTX Major Shareholders This page (NASDAQ:ERNA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
